Accordingly, we evaluated the effect of TCH-165 and bortezomib (BTZ) in primary cells isolated by CD138+ enrichment from a newly diagnosed patient and a BTZ refractory MM patient. This evidence concerns the gene SDC1 and Miyoshi myopathy.